Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMHDF7B)

• Drug Name: Thiamylal Drug Info
• Synonyms: Surital; Thioquinalbarbitone; Thioseconal; Thiamylal [USAN]; Surital (TN); Barbituric acid, 5-allyl-5-(1-methylbutyl)-2-thio-(VAN); Barbituric acid, 5-allyl-5-(1-methylbutyl)-2-thio-(VAN) (8CI); Dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-4,6(1H,5H)-pyrimidinedione; Dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-4,6-(1H,5H)-pyrimidinedione; 4,6(1H,5H)-Pyrimidinedione, dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-(9CI); 5-(pentan-2-yl)-5-(prop-2-en-1-yl)-2-sulfanylidenedihydropyrimidine-4,6(1H,5H)-dione; 5-Allyl-5-(1-methylbutyl)-2-thiobarbituric acid; 5-Allyl-5-(1-methylbutyl)-2-thiobarbitursaeure; 5-Allyl-5-(1-methylbutyl)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione; 5-allyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione; 5-pentan-2-yl-5-prop-2-enyl-2-sulfanylidene-1,3-diazinane-4,6-dione
• Therapeutic Class: Hypnotics and Sedatives
• Cross-matching ID:
  PubChem CID: 3032285
  ChEBI ID: CHEMBL9536
  CAS Number: CAS 77-27-0
  TTD Drug ID: D06NSA
  INTEDE Drug ID: DR1579

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Graft-versus-host disease	2.56	0.00e+0	32/42 (76.19%)	HLA-DRB1;HLA-DRA;HLA-DQA1;...
Systemic lupus erythematosus	2.50	0.00e+0	45/135 (33.33%)	CD40;HLA-DRB1;HLA-DRA;...
Allograft rejection	2.48	0.00e+0	32/38 (84.21%)	CD40;HLA-DRB1;HLA-DRA;...
Antigen processing and presentation	2.45	0.00e+0	60/78 (76.92%)	HLA-DRB1;HLA-DRA;HLA-DQA1;...
Staphylococcus aureus infection	2.38	0.00e+0	72/95 (75.79%)	HLA-DRB1;KRT15;HLA-DRA;...
Autoimmune thyroid disease	2.31	0.00e+0	46/53 (86.79%)	CD40;HLA-DRB1;HLA-DRA;...
Viral protein interaction with cytokine and cytokine re...	2.27	0.00e+0	84/100 (84%)	CXCL2;CXCL1;TNFSF10;...
Viral myocarditis	2.26	0.00e+0	53/60 (88.33%)	CD40;HLA-DRB1;HLA-DRA;...
Type I diabetes mellitus	2.26	0.00e+0	38/43 (88.37%)	HLA-DRB1;HLA-DRA;HLA-DQA1;...
Intestinal immune network for IgA production	2.25	0.00e+0	38/48 (79.17%)	CD40;HLA-DRB1;HLA-DRA;...
Asthma	2.22	1.00e-3	25/31 (80.65%)	CD40;HLA-DRB1;HLA-DRA;...
IL-17 signaling pathway	2.16	9.17e-4	84/94 (89.36%)	CXCL2;CXCL1;S100A8;...
Inflammatory bowel disease	2.07	1.69e-3	58/65 (89.23%)	HLA-DRB1;HLA-DRA;HLA-DQA1;...
Rheumatoid arthritis	2.03	1.57e-3	78/93 (83.87%)	CXCL2;CXCL1;HLA-DRB1;...
Amoebiasis	2.00	1.47e-3	99/102 (97.06%)	CXCL2;CXCL1;CXCL8;...
Natural killer cell mediated cytotoxicity	1.93	1.38e-3	99/131 (75.57%)	TNFSF10;PAK1;CD48;...
Influenza A	1.86	5.18e-3	156/172 (90.7%)	TNFSF10;HLA-DRB1;CXCL8;...
Epstein-Barr virus infection	1.82	7.34e-3	189/202 (93.56%)	CD40;HLA-DRB1;HLA-DRA;...
Epithelial cell signaling in Helicobacter pylori infect...	1.81	8.11e-3	62/70 (88.57%)	CXCL2;CXCL1;PAK1;...
Herpes simplex virus 1 infection	1.79	1.10e-2	165/498 (33.13%)	HLA-DRB1;HLA-DRA;HLA-DQA1;...
Chemokine signaling pathway	1.78	1.15e-2	163/192 (84.9%)	CXCL2;CXCL1;CCL4;...
Phagosome	1.76	1.40e-2	118/152 (77.63%)	HLA-DRB1;HLA-DRA;HLA-DQA1;...
African trypanosomiasis	1.76	1.44e-2	32/37 (86.49%)	TNF;SELE;APOA1;...
DNA replication	1.73	1.83e-2	34/36 (94.44%)	RFC5;RFC2;RNASEH2A;...
TNF signaling pathway	1.72	2.07e-2	103/112 (91.96%)	CXCL2;CXCL1;CXCL6;...
Leishmaniasis	1.71	2.29e-2	67/77 (87.01%)	HLA-DRB1;HLA-DRA;HLA-DQA1;...
Cytokine-cytokine receptor interaction	1.71	2.20e-2	246/295 (83.39%)	CXCL2;CXCL1;TNFSF10;...
Drug metabolism	1.69	2.69e-2	78/151 (51.66%)	GSTA1;IMPDH2;GSTP1;...
Human T-cell leukemia virus 1 infection	1.68	2.60e-2	197/219 (89.95%)	CD40;HLA-DRB1;HLA-DRA;...
Th17 cell differentiation	1.68	2.52e-2	95/107 (88.79%)	HLA-DRB1;HLA-DRA;HLA-DQA1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Ewing sarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
SK-ES-1	CVCL_0627	Homo sapiens	1.11uM - 10uM	24H	Hide ▲

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H	Hide ▲

Brain

Glioma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
GI-1	CVCL_1230	Homo sapiens	1.11uM - 10uM	24H	Show ▼

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MDA-MB-468	CVCL_0419	Homo sapiens	1.11uM - 10uM	24H	Show ▼

Breast ductal carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
T-47D	CVCL_0553	Homo sapiens	1.11uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
SNU-407	CVCL_5004	Homo sapiens	1.11uM - 10uM	24H	Show ▼

Endometrium

Endometrial adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEC-108	CVCL_2926	Homo sapiens	1.11uM - 10uM	24H	Show ▼
HEC-1-A	CVCL_0293	Homo sapiens	1.11uM - 10uM	24H	Show ▼
HEC-251	CVCL_2928	Homo sapiens	1.11uM - 10uM	24H	Show ▼
HEC-265	CVCL_2929	Homo sapiens	1.11uM - 10uM	24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
CJM	CVCL_U797	Homo sapiens	1.11uM - 10uM	24H	Show ▼

Liver

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
JHH-5	CVCL_1320	Homo sapiens	1.11uM - 10uM	24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
NCI-H1573	CVCL_1483	Homo sapiens	1.11uM - 10uM	24H	Show ▼
NCI-H838	CVCL_1594	Homo sapiens	1.11uM - 10uM	24H	Show ▼

Lung squamous cell carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
BEN	CVCL_1081	Homo sapiens	1.11uM - 10uM	24H	Show ▼
HCC95	CVCL_1276	Homo sapiens	1.11uM - 10uM	24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
NCI-H2110	CVCL_1529	Homo sapiens	1.11uM - 10uM	24H	Show ▼

Muscle

Rhabdomyosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-204	CVCL_0134	Homo sapiens	1.11uM - 3.33uM	24H	Show ▼

Ovary

Ovarian clear cell carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
OVTOKO	CVCL_3114	Homo sapiens	1.11uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
22Rv1	CVCL_1045	Homo sapiens	1.11uM - 10uM	24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
IGR-37	CVCL_1303	Homo sapiens	1.11uM - 10uM	24H	Show ▼
Mel-HO	CVCL_1402	Homo sapiens	1.11uM - 10uM	24H	Show ▼
SH-4	CVCL_1692	Homo sapiens	1.11uM - 10uM	24H	Show ▼

Urinary bladder

Bladder carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
BC-3C	CVCL_1079	Homo sapiens	1.11uM - 10uM	24H	Show ▼

Bladder transitional cell carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
CAL-29	CVCL_1109	Homo sapiens	1.11uM - 10uM	24H	Show ▼